GlassScriptPhysician profile
Sandy Rozema
NPI 1750761425
$5,043.72
in general payments reported to CMS, 2019-2025
23 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $687 · 2023: $840 · 2024: $1,252 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,769.21 | 2021-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $978.81 | 2021-2025 | Lynparza, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $646.61 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $328.79 | 2021-2025 | Keytruda, Lynparza |
| Eisai INC. | $265.76 | 2021-2025 | |
| Seagen INC. | $166.26 | 2021-2023 | Tukysa |
| Immunogen, INC. | $155.75 | 2023-2024 | Elahere, Elahere |
| Puma Biotechnology, INC. | $116.66 | 2024 | |
| Abbvie INC. | $112.44 | 2024-2025 | |
| Stemline Therapeutics INC. | $90.67 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $64.14 | 2023-2024 | |
| Lilly USA, LLC | $61.44 | 2021-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $52.50 | 2021-2024 | Jemperli, Zejula |
| Foundation Medicine, INC. | $41.80 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $29.22 | 2021-2023 | Libtayo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.57 | 2021-2024 | |
| Clovis Oncology, INC. | $27.82 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.30 | 2024 | Cosela |
| Cumberland Pharmaceuticals, INC. | $19.58 | 2024 | Sancuso |
| Janssen Scientific Affairs, LLC | $17.82 | 2024 | Erleada |
| Janssen Biotech, INC. | $16.55 | 2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $16.04 | 2024 | Opdivo |
| Incyte Corporation | $15.98 | 2024 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Rozema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.